Subscriber access provided by University of Otago Library
Article
Amelioration of Experimental Autoimmune Encephalomyelitis by Isogarcinol Extracted from Garcinia mangostana L. Mengqi Wang, Yufei Xie, Youxiu Zhong, Juren Cen, Lei Wang, Yuanyuan Liu, Ying Zhu, Li Tong, and Qun Wei J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.6b04145 • Publication Date (Web): 07 Nov 2016 Downloaded from http://pubs.acs.org on November 14, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 35
Journal of Agricultural and Food Chemistry
1
Amelioration of Experimental Autoimmune Encephalomyelitis by Isogarcinol
2
Extracted from Garcinia mangostana L.
3 4
Mengqi Wang†, Yufei Xie†, Youxiu Zhong†‡, Juren Cen†§, Lei Wang†, Yuanyuan Liu†,
5
Ying Zhu†, Li Tong†, Qun Wei†*
6 7
† Department of Biochemistry and Molecular Biology, Beijing Normal University,
8
Gene Engineering and Biotechnology Beijing Key Laboratory, Beijing 100875,
9
People’s Republic of China
10
‡ National Vaccine and Serum Institute, Beijing 100024, People’s Republic of China
11
§ Key Laboratory of Protection and Development Utilization of Tropical Crop
12
Germplasm Resources, Ministry of Education, College of Landscape and Horticulture,
13
Hainan University, Haikou 570228, People’s Republic of China
14 15
* Corresponding author
16
Tel: 86-010-58807365. Fax: 86-010-58807365. E-mail:
[email protected].
17
1
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
18
ABSTRACT
19
Isogarcinol is a new natural immunosuppressant that was extracted from Garcinia
20
mangostana L. in our laboratory. Knowledge of its effects on treatable diseases and its
21
mechanism of action is still very limited. In this study, we explored the therapeutic
22
effect of isogarcinol in experimental autoimmune encephalomyelitis (EAE), a murine
23
model of multiple sclerosis (MS). Treatment with oral 100 mg/kg isogarcinol
24
markedly ameliorated clinical scores, alleviated inflammation and demyelination of
25
the spinal cord, and reduced intracranial lesions in EAE mice. The percentages of Th
26
cells and macrophages were also strongly reduced. Isogarcinol appeared to act by
27
inhibiting T helper (Th) 1 and Th17 cell differentiation via the Jak/STAT pathway, and
28
impairing macrophage function. Our data suggest that isogarcinol has the potential to
29
be an effective therapeutic agent of low toxicity for treating MS and other
30
autoimmune diseases.
31 32
KEYWORDS: Garcinia mangostana L., isogarcinol, experimental autoimmune
33
encephalomyelitis, multiple sclerosis, cytokines, Jak/STAT pathway
34
2
ACS Paragon Plus Environment
Page 2 of 35
Page 3 of 35
Journal of Agricultural and Food Chemistry
35
INTRODUCTION
36
Multiple sclerosis (MS) is a common and disabling autoimmune disease of the central
37
nervous system (CNS) in young adults.1 Underling MS is chronic multifocal
38
inflammatory demyelination of the white matter of the CNS, and dysfunction of the
39
blood brain barrier (BBB), which results in a range of clinical symptoms, including
40
physical and mental disabilities.1-3 There were about 2.3 million people suffering from
41
MS in 2013, and the ratio of female to male patients was 2: 1.4 Although the cause of
42
MS is unknown, one theory is that it is triggered by immune system destruction of
43
myelin,5 and there is evidence that autoreactive T helper (Th) cells are critically
44
involved in the development of MS.5-7 Experimental autoimmune encephalomyelitis
45
(EAE) is a T-cell-mediated autoimmune disease displaying the key characteristics of
46
human MS; it is therefore widely used as a preclinical model of MS.8 The model can
47
be induced either by immunizing animals with a variety of antigens, such as myelin
48
proteins, CNS homogenate and so on, or by adoptive transfer of encephalitogenic T
49
cells. 9 In general, the clinical symptoms of EAE are progressive paralysis and weight
50
loss. More importantly, EAE can mimic the typical neuropathological characteristics
51
of MS, such as inflammatory demyelination and destruction of the BBB. The
52
development of MS and EAE has been attributed to large numbers of Th1 and Th17
53
cytokine-secreting CD4+ T cells. 10, 11
54
MS is still incurable, but several treatments have proven effective. It is generally
55
treated with immunomodulators such as glucocorticoid, intravenous immune globulin,
56
interferon beta, glatiramer acetate, methotrexate, cyclophosphamide, etc.12-17 The
57
calcineurin (CN) inhibitor, cyclosporine A (CsA), which has outstanding
58
immunosuppressive and anti-inflammatory effects, is also a commonly used oral drug
59
for MS patients in the clinic.18 Although some of these drugs are given orally, most of 3
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 4 of 35
60
those used in MS are given by intravenous or subcutaneous injection, which is painful
61
and inconvenient and carries a high risk of infection. Moreover, these drugs can only
62
slow down the progression of the disease, and often have significant adverse effects in
63
long-term
64
nephrotoxicity and cardiotoxicity.19 Therefore, the development of an oral drug with
65
high efficacy and low toxicity is urgently needed.
therapy
including
depression,
nausea,
anemia,
hepatotoxicity,
66
It is generally recognized that increasing fruit consumption is a safe way to reduce
67
the incidence of cancers, cardiovascular disease and inflammatory and autoimmune
68
diseases.20-22 The mangosteen (Garcinia mangostana L.), is a tropical evergreen tree
69
originating in the Sunda Islands and the Moluccas of Indonesia, which is well-known
70
for its sweet, slightly acid-tasting fruit. This consists of a milky-white edible portion
71
and a purple pericarp. There is a long history of use of the fruit, especially its pericarp,
72
to treat diarrhea, dysentery and skin and wound infections.23 Recent studies have
73
shown that extracts of mangosteen have anti-inflammatory, antitumor, antioxidant and
74
antibacterial activities,24, 25 and that it can to treat diarrhea, dysentery and skin and
75
wound infections, as well as ameliorating Alzheimer's disease and diabetes.26
76
CN is generally used as a
target for screening potential immunosuppressive
77
agents, and our laboratory has built a mature system for identifying CN inhibitors
78
among natural products.27,
79
mangostana L. fruit in our laboratory, inhibits CN activity, but its mechanism of
80
action differs from that of CsA. In previous work we showed that it inhibits the
81
proliferation of spleen T-lymphocytes induced by concanavalin A (ConA), as well as
82
the mixed lymphocyte reaction, and has an excellent therapeutic effect in a variety of
83
animal models, including those of delayed type hypersensitivity (DTH), graft survival
84
in allogeneic skin transplantation, rheumatoid arthritis (RA) and Systemic Lupus
28
Isogarcinol (Figure 1A), extracted from Garcinia
4
ACS Paragon Plus Environment
Page 5 of 35
Journal of Agricultural and Food Chemistry
85
Erythematosus (SLE).27, 29, 30
86
Isogarcinol also has anti-inflammatory activity both in vitro and vivo.29 More
87
importantly, it was less hepatotoxic and nephrotoxic than CsA in experimental
88
animals. Therefore, it may be a safer immunosuppressant. In this study, we explored
89
its effects on inflammatory/autoimmune disorders and its possible mode of action in
90
the EAE model.
91
MATERIALS AND METHODS
92
Mice and drug. Female C57BL/6 mice (6–8 weeks) were purchased from Beijing
93
Vital River (Beijing, China). All mice were maintained under standard conditions with
94
standard mouse chow and water ad libitum. All animal experimental procedures were
95
authorized by the Animal Ethics Committee of Beijing Normal University (NO.
96
CLS-EAW-2013-015) and were executed in strict accordance with institutional
97
guidelines. Isogarcinol was extracted and purified by J. Cen of our lab, and was more
98
than 95% pure27, 31.
99
Reagents. A Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular
100
Technologies, Inc. (Beijing, China). ConA, complete Freund’s adjuvant (CFA) and
101
dimethyl sulfoxide (DMSO) were from Sigma–Aldrich (St. Louis, MO, USA).
102
35–55
103
(MEVGWYRSPFSRVVHLYRNGK), of purity > 95%, was synthetized by Scilight
104
Biotechnology, LLC (Beijing, China). Mycobacterium tuberculosis H37Ra was from
105
Difco Laboratories (Detroit, MI, USA), pertussis toxin (PTX) from List Biological
106
Laboratories (Campbell, CA, USA), and. Percoll from GE Healthcare (Piscataway, NJ,
107
USA). Flow cytometry antibodies against CD4, CD8, B220 and CD11b, and the
108
mouse Th1/Th2/Th17 Cytokine Kit and Skim Milk were from BD Biosciences (San
109
Jose, CA, USA), and the mouse CD4 isolation kit and MACS separation columns
residue
peptide
of
myelin
oligodendrocyte
5
ACS Paragon Plus Environment
glycoprotein
The
(MOG)
Journal of Agricultural and Food Chemistry
Page 6 of 35
110
were from Miltenyi (Germany). RPMI 1640, fetal bovine serum (FBS) and TRIzol
111
reagent were from Life Technologies (Carlsbad, CA, USA), and oligo dT Primer,
112
dNTP mixture, RNase inhibitor, Reverse Transcriptase M-MLV and SYBR Premix Ex
113
Taq were from TaKaRa Bio (Kusatsu, Shiga, Japan). The bicinchonininc acid (BCA)
114
protein quantitation kit was purchased from Thermo Fisher Scientific (San Jose, CA,
115
USA), and Western blotting antibodies, the Stat Antibody Sampler Kit and the
116
Phospho-Stat Antibody Sampler Kit were from Cell Signaling Technology (Danvers,
117
MA, USA).
118
EAE induction. EAE was induced as previously described.5,
8
The first
119
immunization day was defined as day 0. Mice were immunized s.c. with 200 µg
120
MOG35–55 and 400 µg Mycobacterium tuberculosis H37Ra emulsified with 200 µl of
121
CFA. Then they were administered i.p. 200 ng PTX in PBS on days 0 and 2
122
postimmunization. The clinical behavior of the mice was examined daily and scored
123
on the standard scale of Kuerten et al.32
124
Preparation of splenocytes, mononuclear cells and CD4+ cells. Brain, spinal
125
cord and spleen were filtered through 70-µm nylon cell strainers to prepare single-cell
126
suspensions. MNCs from the CNS were purified using a 37/70% Percoll gradient at
127
780 g for 25 min (4 ℃). CD4+ cells were purified by negative selection MACS with a
128
Miltenyi CD4 isolation kit.
129
ConA/MOG35-55-induced T cell proliferation. Splenocytes (5×105 per well in
130
96-well plates) derived from EAE mice stimulated with MOG35-55 (20 µg/mL), and
131
normal congenic mice stimulated with ConA (5 µg/mL), were cultured with different
132
concentrations of isogarcinol (2.5, 5 and 10 µM) for up to 48 h. Proliferation was
133
measured with the CCK-8 assay and growth inhibition was calculated from the
134
equation: viability (%) = (OD450 of isogarcinol group / OD450 of control group) ×100. 6
ACS Paragon Plus Environment
Page 7 of 35
Journal of Agricultural and Food Chemistry
135
Drug administration. For treatment, isogarcinol (100 mg/kg) or CsA (50 mg/kg)
136
was given daily starting 11 d after immunization until 28 days postimmunization. The
137
naïve and vehicle groups received the same volume of solvent (23% ddH2O, 12%
138
ethanol, 60% peanuts oil and 5% Tween-80) as the treatment group. The dosages were
139
based on our previous findings. 27, 29
140
Histopathological Analysis. Spinal cords were obtained from animals and
141
immediately fixed in 4% paraformaldehyde. After being embedded in paraffin, they
142
were cut and stained with Hematoxylin and Eosin (H&E), and Luxol Fast Blue (LFB).
143
Inflammation and demyelination were assessed according to Wei et al and Li et al.33,
144
34
145
Magnetic resonance imaging (MRI). MRI experiments were performed on a
146
3.0-T scanner (Prisma, Siemens Healtcare, ER, GER). Mice were anesthetized with 1%
147
nembutal and scanned for T1-weighted images (TR/TE = 433.2/11, FOV = 17 × 24,
148
matrix acquisition = 256 × 389, slice thickness = 0.5 mm). Gd-DTPA-enhanced T1
149
images, with scan sequences the same as for T1, were made after i.p. injection of 0.5
150
mmol/kg gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA).
151
Drug toxicity in EAE mice. To compare the toxicity of isogarcinol and CsA, blood
152
samples of treated EAE mice were collected to measure biochemical parameters and
153
carry out routine blood test.
154
Cell population analyses and cytokine measurements. Splenocytes and MNCs
155
from the CNS were prepared as described above and incubated with
156
fluorochrome-conjugated antibodies to CD4, CD8, B220, and CD11b. Culture
157
supernatants were collected from 20 µg/mL MOG-stimulated splenocytes after 48 h to
158
measure concentrations of IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A and IL-10 with a
159
Th1/Th2/Th17 Cytokine Kit by flow cytometry. 7
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 8 of 35
160
Real-time PCR for transcription factors related to Th cell differentiation. Total
161
RNA was extracted from CD4+ T cells and MNCs with TRIzol reagent. cDNA
162
synthesis and relative quantitative real-time PCR were performed according to the
163
manufacturer’s instructions. The mRNA levels of T-bet, GATA3, RORγt and Foxp3
164
genes were analyzed with an Applied Biosystems 7500. The sequences of the primers
165
used were as follows: β-actin, AGAGGGAAATCGTGCGTGAC (forward) and
166
CAATAGTGATGACCTGGCCGT (reverse); T-bet, GTTCAACCAGCACCAGACA-
167
GAG (forward) and TGGTCCACCAAGACCACATC (reverse); GATA3, GGATGT-
168
AAGTCGAGGCCCAAG
169
(reverse); RORγt, TCTGCAAGACTCATCGACAAGG (forward) and CACATGTT-
170
GGCTGCACAGG (reverse); Foxp3, TGCCTTCAGACGAGACTTGGA (forward)
171
and GGCATTGGGTTCTTGTCAGAG (reverse).
(forward)
and
ATTGCAAAGGTAGTGCCCGGTA
172
Western blot analysis of the Jak/STAT signaling pathway. Protein samples were
173
obtained by centrifugation after 24 h stimulation with MOG35-55 (20 µg/mL). A BCA
174
kit was used to measure protein concentrations. The samples were electrophoresed on
175
SDS-PAGE, and transferred to PVDF membranes. The membranes were blocked with
176
5% skim milk powder in TBST (TBS + 1‰ Tween-20) and blotted with primary and
177
secondary
178
electrochemiluminescence (ECL) kit.
antibodies.
Specific
bands
were
visualized
with
an
179
Statistics. Data are expressed as means ± SEM. Student’s t-tests were used to
180
analyze differences between paired samples. Other differences were assessed by
181
one-way ANOVA. p values < 0.05 were deemed statistically significant.
182
RESULTS
183
Isogarcinol inhibits the proliferation of Encephalitogenic T Cells and
184
efficiently ameliorates the Clinical Symptoms of EAE Mice. Splenocytes from 8
ACS Paragon Plus Environment
Page 9 of 35
Journal of Agricultural and Food Chemistry
185
EAE mice stimulated with MOG35-55 (20 µg/mL) or from normal congenic mice
186
stimulated with ConA (5 µg/mL) were cultured in the presence of different
187
concentrations of isogarcinol, and their proliferation was measured using the CCK-8
188
assay after 48 h. The concentration of isogarcinol used was based on our previous
189
study of ConA-stimulated T cells proliferation.27 As shown in Figure 1B, isogarcinol
190
inhibited the proliferation of encephalitogenic T cells induced by MOG35-55 at a low
191
concentration (2.5 µM), whereas a concentration of up to 10 µM was needed to inhibit
192
ConA-induced nonspecific proliferation. This result suggested that encephalitogenic T
193
cells were very sensitive to isogarcinol treatment. Therefore, we examined the effect
194
of isogarcinol on the development of an EAE model. C57BL/6 mice were immunized
195
as described in MATERIALS AND METHODS, and divided into 3 groups of vehicle,
196
isogarcinol and CsA mice. EAE developed in 100% of the mice in all 3 groups, with,
197
as expected, very similar onset times. Isogarcinol (100 mg/kg) or CsA (50 mg/kg)
198
treatments were started from day 11 postimmunization, when the disease generally
199
develops in mice, and was continued daily thereafter. As shown in Figure 2A,
200
isogarcinol significantly decreased disease severity, as did CsA. The body weights of
201
the isogarcinol/ CsA- treated mice were unaffected at the peak of the disease (Figure
202
2B).
203
Isogarcinol Treatment Alleviates Inflammation and Demyelination in the
204
Brain and Spinal Cord. Inflammatory infiltration and demyelination in the CNS, and
205
BBB lesions, are typical characteristics of MS and EAE.1, 3 Histological studies of
206
spinal cords were carried out on day 18, and the results are shown in Figure 2C.
207
Compared with healthy mice, infiltration of a large number of inflammatory cells and
208
large areas of demyelination can be seen in H&E and LFB staining of the
209
vehicle-treated mice. Infiltration and demyelination were greatly reduced in the mice 9
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
210
treated with isogarcinol or CsA (Figure 2D and 2E). At the same time, the number of
211
CNS MNCs was clearly reduced by isogarcinol (Figure 2F). Since the integrity of the
212
BBB can be evaluated by imaging, we used MRI to check for intracranial signal
213
changes in the mice on day 18 post-immunization. A number of sporadic hyperintense
214
lesions were observed in the vehicle-treated mice after injection with Gd-DTPA,
215
indicating damage to the BBB. In contrast, no abnormal signals appeared in the
216
isogarcinol or CsA-treated mice (Figure 3). These results show that isogarcinol can
217
prevent intracranial lesions in MOG35-55-treated mice.
218
Isogarcinol has no significant Toxicity in the EAE Model.
219
To evaluate any toxic side effects of isogarcinol in the EAE model, biochemical
220
and hematological parameters were examined. Blood samples of the mice were
221
collected on day 28. As shown in Figures 4 and 5, treatment with 100 mg/kg
222
isogarcinol did not cause any major hematopoietic or biochemical changes in the mice,
223
whereas treatment with 50 mg/kg CsA led to a reduced red blood cell count (P =
224
0.0048) and increased alkaline phosphatase (ALP, P = 0.0055) and total bilirubin
225
(TBIL, P = 0.0024) levels. CsA also raised platelet numbers and creatinine (CRE)
226
levels compared with the isogarcinol group, but the effects were not statistically
227
significant.
228
Isogarcinol reduces activation of the CD4+ and CD11b+ Cell Populations. There
229
is some evidence that the tissue damage in MS and EAE is correlated with certain
230
immune responses. 8, 35 We therefore isolated MNCs from the spleens and CNS of the
231
mice, and used flow cytometry to analyze the percentage expression of surface CD4,
232
CD8, B220, and CD11b, representing Th cells, cytotoxic T cells, B cells and
233
infiltrated macrophages/microglia, respectively. The percentages of CD4+ (spleen, P =
234
0.0011; CNS, P = 0.0002) and CD11b+ (spleen, P = 0.0152; CNS, P = 0.0073) cells 10
ACS Paragon Plus Environment
Page 10 of 35
Page 11 of 35
Journal of Agricultural and Food Chemistry
235
were significantly reduced by isogarcinol in both spleen and CNS. However, the
236
percentages of CD8+ and B220 cells were not altered (Figure 6).
237
Isogarcinol reduces numbers of Th1 and Th17 by inhibiting the Jak/STAT
238
Signaling Pathway. Since isogarcinol inhibited the activation of CD4+ T cells, we
239
investigated the subset of Th cells affected by it. Because the differentiation of Th
240
cells is promoted by the Jak/STAT pathway, we hypothesized that isogarcinol affects
241
the STAT protein family. Protein samples were obtained from isogarcinol- and
242
vehicle-treated mice as described in MATERIALS AND METHODS. As shown in
243
Figure 7A and B, the phosphorylation levels of STAT1 and STAT3, which are closely
244
related to the differentiation of Th1 and Th17 cells, were markedly reduced in
245
isogarcinol-treated mice, whereas STAT6 and STAT5, whose levels are related to Th2
246
and Treg cell differentiation, were not affected. We then used CD4+ cells, obtained
247
from spleen and CNS, to detect the expression of key transcription factors regulated
248
by the STAT family. T-bet for Th1 cells and RORγt for Th17 cells were
249
down-regulated in the isogarcinol-treated mice, whereas GATA3 representing Th2
250
cells and Foxp3 representing Treg cells were unaltered (Figure 7C). To confirm the
251
effect of isogarcinol on Th1 and Th17 cells, we measured cytokines related to Th cells
252
in the supernatants of splenocytes stimulated ex vivo with 20 µg/mL MOG35-55 for 48
253
h. In contrast to the vehicle-treated group, isogarcinol significantly reduced the
254
production of both the Th1-related proinflammatory cytokines IFN-γ (P = 0.0137)
255
and TNF-α (P = 0.0373) and the Th17-related cytokine IL-17A (P = 0.0365). In
256
addition, it had a small effect effect on IL-6, which is also a Th17-related cytokine
257
(Figure 7D, left). Isogarcinol had no effect on cytokines IL-4, related to Th2 cells, and
258
IL-2 and IL-10, related to Treg cells (Figure 7D, right). These results together indicate
259
that isogarcinol selectively inhibits the Jak/STAT signaling pathway and the 11
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
260
production of proinflammatory cytokines (e.g., TNF-α and IL-6) and so reduces the
261
symptoms of EAE mice.
262
DISCUSSION
263
MS is the commonest autoimmune disorder of the CNS, and its frequency increases
264
year by year.36 Isogarcinol is a new immunosuppressant with dramatic effects on
265
many immune-related diseases, such as acute inflammation, autoimmune diseases,
266
etc.27, 29, 30 Therefore, we wished to explore whether it is effective against MS, and, if
267
so, to understand its mechanism of action. The EAE murine model has been used to
268
test novel agents for treating MS, and the MOG35-55 peptide-induced C57BL/6 mouse
269
is popular in EAE studies.37 Since female MS patients far outnumber males, we
270
immunized female C57BL/6 mice with the MOG35-55 peptide to generate the EAE
271
disease model. To determine the therapeutic properties of isogarcinol in EAE, we first
272
examined the inhibitory effect of isogarcinol on the in vitro proliferation of
273
encephalitogenic T cells induced by MOG35-55, before carrying out in vivo studies. We
274
found that 2.5 µM isogarcinol markedly inhibited proliferation induced by MOG35-55,
275
but not by ConA. This result indicated that isogarcinol might be effective in EAE.
276
MS is characterized by physical and mental clinical signs, including perivascular
277
infiltration of T lymphocytes, demyelination of the white matter of the CNS and
278
multifocal points, and destruction of the blood brain barrier, as seen by histopathology
279
and MRI.37, 38 In our experiments we used clinical scores, H&E staining, LFB staining
280
and MRI to evaluate the EAE model. We found that the number of infiltrating cells in
281
the model group was significantly higher than in the controls, and there was extensive
282
demyelination. Several foci were evident on the MRI scans of the model mice,
283
reflecting the acute inflammation and damage to the BBB; the meninges were also
284
enhanced in Gd-DTPA-enhanced T1 images, due to the damaged BBB, all these 12
ACS Paragon Plus Environment
Page 12 of 35
Page 13 of 35
Journal of Agricultural and Food Chemistry
285
effects resembled those in MS patients.39-41 Thus, together with clinical scores, the
286
data demonstrated that we had successfully established an EAE model. We then used
287
100 mg/kg isogarcinol to treat the sick mice, and found it greatly improved clinical
288
scores and the pathological changes in the brains and spinal cords of the EAE mice.
289
CD4+ Th cells exert their function by regulating other immune cells of the adaptive
290
immune system, and they differentiate into at least four major subsets, i.e., Th1, Th2,
291
Th17, and regulatory T (Treg) cells in response to various factors induced by the
292
Jak/STAT signaling pathway.42 CD4+ T cells play a critical role in the pathogenesis of
293
MS and EAE, and the main reason for the encephalomyelitis of EAE mice is that Th1
294
and Th17 cells cause activation of the microglia and macrophage infiltration.43, 44 The
295
differentiation of Th1 cells, which secrete IFN-γ and TNF-α, depends on IFN-γ
296
activation of STAT1 to increase expression of the transcription factor T-bet. Also
297
IL-17-secreting Th17 cells differentiate in response to IL-6 phosphorylation of STAT3
298
and further induce the transcription factor, RORγt. The Th1-secreted cytokines IFN-γ
299
and TNF-α, and Th17-secreted cytokine IL-17, are markedly increased in both MS
300
and EAE.38, 45 In this study, isogarcinol decreased the percentage of CD4+ Th cells,
301
and down-regulated the concentrations of secreted Th1 and Th17. These effects were
302
all dependent on inhibition of the Jak/STAT signaling pathway: isogarcinol inhibited
303
the phosphorylation of STAT1 thus reducing T-bet expression and reducing the
304
differentiation of Th1 cells and interfering with cytokine secretion. Similarly, it
305
reduced the expression of RORγt by inhibiting the phosphorylation of STAT3, so
306
reducing the number of Th17 cells and blocking cytokine secretion. In addition, there
307
is ample evidence that levels of intracellular ROS can be modified by Th17
308
differentiation. Tse et al. and Ghoreschi et al. reported that the phenotype of Th17 was
309
skewed in T cells from ROS-deficient mice, and these mice were more susceptible to 13
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
310
EAE.46, 47 Since we recently showed that isogarcinol increased ROS in A549 and
311
SMMC-7721 (data unpublished), and others have shown that isogarcinol increased
312
ROS in HL-60 cells,48 this suggests that it may reduce Th1 and Th17 cells by
313
increasing ROS levels.
314
Macrophages as antigen-presenting cells (APCs) have the capacity to activate
315
immune responses and mediate inflammatory reactions. Activation of macrophages,
316
which damages CNS structures and leads to progressive paralysis, also plays an
317
important role in MS and EAE.49 Therefore, we explored the effect of isogarcinol on
318
macrophages by measuring the proportion of CD11b+ cells and the concentration of
319
pro-inflammatory cytokines in the EAE model. The results showed that isogarcinol
320
impaired the functioning of macrophages, and downregulated levels of TNF-α, IL-6
321
and IL-17. It is worth mentioning that in previous work we found that isogarcinol
322
suppressed the inflammatory response induced by LPS in murine macrophage RAW
323
264.7, and had anti-inflammatory activity in mouse RA and SLE models29, 30. Hence
324
we believe that isogarcinol reduces the paralysis, inflammatory cell infiltration and
325
intracranial inflammation of EAE mice by weakening macrophage function.
326
Moreover, as TNF-α and IL-17 are also products of Th1 and Th17 cells, it is likely
327
that isogarcinol regulates Th1 and Th17 cells in EAE mice at least in part via its
328
anti-inflammatory effect.
329
CsA, the inhibitor of CN, is still the most popular immunosuppressant and is
330
commonly used in MS patients.18, 50 We showed above that 50 mg/kg CsA had the
331
same effect as 100 mg/kg oral isogarcinol in improving the clinical signs of EAE mice.
332
However, the EAE mice of the CsA-treated group had reduced numbers of red blood
333
cells and increased ALP and TBIL, reflecting hematological and hepatic toxicity. In
334
our previous study we showed CsA caused extensive death of mouse spleen cells and 14
ACS Paragon Plus Environment
Page 14 of 35
Page 15 of 35
Journal of Agricultural and Food Chemistry
335
had a greater effect on biochemical indicators of liver and kidney function than
336
isogarcinol.27 Furthermore, in those experiments, the CsA group mice were less active
337
and displayed more fur ruffling than the other mice. Overall isogarcinol has less toxic
338
side effects, which is an obvious advantage in long-term treatment.
339
To sum up, we have shown that isogarcinol probably alleviates the clinical signs of
340
EAE by suppressing Th1//Th17 responses by inhibiting the Jak/STAT signaling
341
pathway and by its anti-inflammatory activity. Thus isogarcinol could be an effective
342
drug against MS with low toxicity. The properties of isogarcinol remind us that we
343
should pay more attention to seeking compounds from fruit and agricultural products
344
that may have immunosuppressive, anti-inflammatory and other functions.
345 346
ABBREVIATIONS USED
347
APCs, anti-presenting cells; ALP, alkaline phosphatase; ALT, glutamic-pyruvic
348
transaminase; AST, Glutamic-oxalacetic transaminase; BBB, blood brain barrier;
349
BCA, bicinchonininc acid; BUN, urea nitrogen; CCK-8, Cell Counting Kit-8; CFA,
350
complete Freund’s adjuvant; CN, calcineurin; CNS, central nervous system; ConA,
351
concanavalin A; CRE, creatinine; CsA, cyclosporine A; DMSO, dimethyl sulfoxide;
352
DTH,
353
encephalomyelitis; Gd-DTPA, gadolinium-diethylenetriaminepentaacetic acid; H&E,
354
Hematoxylin and Eosin; HGB, hemoglobin; IFN-γ, interferon gamma; IL, interleukin;
355
LFB, Luxol Fast Blue; MNCs, mononuclear cells; MOG, myelin oligodendrocyte
356
glycoprotein; MS, multiple sclerosis; MRI, magnetic resonance imaging; NFκB,
357
nuclear factor kappa B; PLT, platelet; PTX, pertussis toxin; RA, rheumatoid arthritis;
358
SLE, systemic lupus erythematosus; STAT, signal transducers and activators of
359
transcription; TBIL, total bilirubin; Th, T helper; Jak, janus kinase; TNF-α, tumor
delayed
type
hypersensitivity;
EAE,
experimental
15
ACS Paragon Plus Environment
autoimmune
Journal of Agricultural and Food Chemistry
360
necrosis factor alpha; RBC, red blood cell; ROS, reactive oxygen species; WBC,
361
white blood cell.
362 363 364 365
Funding
366
This work was supported by the National Natural Science Foundation of China, the
367
National Important Novel Medicine Research Project, the Fundamental Research
368
Funds for the Central Universities, and the special fund of the co-construction project
369
of the Beijing Education Committee.
370
Notes
371
The authors declare no competing financial interests.
372
16
ACS Paragon Plus Environment
Page 16 of 35
Page 17 of 35
Journal of Agricultural and Food Chemistry
373
REFERENCES
374
(1) Friese, M. A.; Montalban, X.; Willcox, N.; Bell, J. I.; Martin, R.; Fugger, L., The
375
value of animal models for drug development in multiple sclerosis. Brain 2006, 129,
376
1940-1952.
377
(2) He, Y.-X.; Du, M.; Shi, H.-L.; Huang, F.; Liu, H.-S.; Wu, H.; Zhang, B.-B.; Dou,
378
W.; Wu, X.-J.; Wang, Z.-T., Astragalosides from Radix Astragali benefits
379
experimental autoimmune encephalomyelitis in C57BL/6 mice at multiple levels.
380
BMC Complement. Altern. Med. 2014, 14, 313.
381
(3) Compston, A.; Coles, A., Multiple Sclerosis. Lancet 2002, 359, 1221-31.
382
(4) Vos, T.; Barber, R. M.; Bell, B.; Bertozzi-Villa, A.; Biryukov, S.; Bolliger, I.;
383
Charlson, F.; Davis, A.; Degenhardt, L.; Dicker, D., Global, regional, and national
384
incidence, prevalence, and years lived with disability for 301 acute and chronic
385
diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the
386
Global Burden of Disease Study 2013. The Lancet 2015, 386, 743-800.
387
(5) Qin, X.; Guo, B. T.; Wan, B.; Fang, L.; Lu, L.; Wu, L.; Zang, Y. Q.; Zhang, J. Z.,
388
Regulation of Th1 and Th17 cell differentiation and amelioration of experimental
389
autoimmune encephalomyelitis by natural product compound berberine. The Journal
390
of Immunology 2010, 185, 1855-1863.
391 392 393 394
(6) Sospedra, M.; Martin, R., Immunology of multiple sclerosis*. Annu. Rev. Immunol. 2005, 23, 683-747. (7) McFarland, H. F.; Martin, R., Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8, 913-919. 17
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
395
(8) Lu, Y.; Chen, B.; Song, J.-H.; Zhen, T.; Wang, B.-Y.; Li, X.; Liu, P.; Yang, X.;
396
Zhang, Q.-L.; Xi, X.-D., Eriocalyxin B ameliorates experimental autoimmune
397
encephalomyelitis by suppressing Th1 and Th17 cells. Proceedings of the National
398
Academy of Sciences 2013, 110, 2258-2263.
399
(9) Gold, R.; Linington, C.; Lassmann, H., Understanding pathogenesis and therapy
400
of multiple sclerosis via animal models: 70 years of merits and culprits in
401
experimental autoimmune encephalomyelitis research. Brain 2006, 129, 1953-71.
402 403
(10) Chitnis, T.; Khoury, S. J., Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol. Res. 2003, 28, 223-239.
404
(11) CL, L.; Y, C.; WM, B.; J, M.; B, B.; JD, S.; T, M.; RA, K.; DJ, C., IL-23 drives
405
a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med.
406
2005, 201, : 233–240.
407
(12) Comi, G.; Filippi, M.; Wolinsky, J. S., European/Canadian multicenter,
408
double‐blind, randomized, placebo‐controlled study of the effects of glatiramer
409
acetate on magnetic resonance imaging–measured disease activity and burden in
410
patients with relapsing multiple sclerosis. Ann. Neurol. 2001, 49, 290-297.
411
(13) Achiron, A.; Gabbay, U.; Gilad, R.; Hassin-Baer, S.; Barak, Y.; Gornish, M.;
412
Elizur, A.; Goldhammer, Y.; Sarova-Pinhas, I., Intravenous immunoglobulin treatment
413
in multiple sclerosis Effect on relapses. Neurology 1998, 50, 398-402.
414
(14) Comi, G.; Filippi, M.; Barkhof, F.; Durelli, L.; Edan, G.; Fernández, O.;
415
Hartung, H.-P.; Seeldrayers, P.; Sørensen, P. S.; Rovaris, M., Effect of early interferon
416
treatment on conversion to definite multiple sclerosis: a randomised study. The Lancet 18
ACS Paragon Plus Environment
Page 18 of 35
Page 19 of 35
Journal of Agricultural and Food Chemistry
417
2001, 357, 1576-1582.
418
(15) Miller, D. M.; Weinstock-Guttman, B.; Béthoux, F.; Lee, J.-C.; Beck, G.; Block,
419
V.; Durelli, L.; LaMantia, L.; Barnes, D.; Sellebjerg, F., A meta-analysis of
420
methylprednisolone in recovery from multiple sclerosis exacerbations. Multiple
421
Sclerosis 2000, 6, 267-273.
422
(16) Goodkin, D. E.; Rudick, R. A.; Medendorp, S. V.; Daughtry, M. M.; Schwetz, K.
423
M.; Fischer, J.; Van Dyke, C., Low‐dose (7.5 mg) oral methotrexate reduces the rate
424
of progression in chronic progressive multiple sclerosis. Ann. Neurol. 1995, 37, 30-40.
425
(17) Comabella, M.; Balashov, K.; Issazadeh, S.; Smith, D.; Weiner, H. L.; Khoury,
426
S. J., Elevated interleukin-12 in progressive multiple sclerosis correlates with disease
427
activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 1998,
428
102, 671.
429
(18) Satake, A.; Schmidt, A. M.; Nomura, S.; Kambayashi, T., Inhibition of
430
calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion
431
and graft-versus-host disease protection by IL-2 in allogeneic bone marrow
432
transplantation. PLoS One 2014, 9, e92888.
433
(19) Castro-Borrero, W.; Graves, D.; Frohman, T. C.; Flores, A. B.; Hardeman, P.;
434
Logan, D.; Orchard, M.; Greenberg, B.; Frohman, E. M., Current and emerging
435
therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 2012, 5,
436
205-220.
437
(20) Hung, H. C.; Joshipura, K. J.; Jiang, R.; Hu, F. B.; Hunter, D.; Smith-Warner, S.
438
A.; Colditz, G. A.; Rosner, B.; Spiegelman, D.; Willett, W. C., Fruit and vegetable 19
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
439
intake and risk of major chronic disease. J. Natl. Cancer Inst. 2004, 96, 1577-1584.
440
(21) Holt, E. M.; Steffen, L. M.; Moran, A.; Basu, S.; Steinberger, J.; Ross, J. A.;
441
Hong, C. P.; Sinaiko, A. R., Fruit and Vegetable Consumption and Its Relation to
442
Markers of Inflammation and Oxidative Stress in Adolescents. J. Am. Diet. Assoc.
443
2009, 109, 414-421.
444
(22) Sirdaarta, J.; Matthews, B.; White, A.; Cock, I. E., GC-MS and LC-MS analysis
445
of Kakadu plum fruit extracts displaying inhibitory activity against microbial triggers
446
of multiple sclerosis. Pharmacognosy Communications 2015, 5, 100-115.
447
(23) Jung, H.-A.; Su, B.-N.; Keller, W. J.; Mehta, R. G.; Kinghorn, A. D.,
448
Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen). J.
449
Agric. Food Chem. 2006, 54, 2077-2082.
450
(24) Pedraza-Chaverri, J.; Cárdenas-Rodríguez, N.; Orozco-Ibarra, M.; Pérez-Rojas,
451
J. M., Medicinal properties of mangosteen ( Garcinia mangostana ). Food & Chemical
452
Toxicology An International Journal Published for the British Industrial Biological
453
Research Association 2008, 46, 3227-39.
454
(25) Moongkarndi, P.; Kosem, N.; Kaslungka, S.; Luanratana, O.; Pongpan, N.;
455
Neungton, N., Antiproliferation, antioxidation and induction of apoptosis by Garcinia
456
mangostana (mangosteen) on SKBR3 human breast cancer cell line. J.
457
Ethnopharmacol. 2004, 90, 161-166.
458
(26) Wang, S.-n.; Li, Q.; Jing, M.-h.; Alba, E.; Yang, X.-h.; Sabaté, R.; Han, Y.-f.; Pi,
459
R.-b.; Lan, W.-j.; Yang, X.-b., Natural Xanthones from Garcinia mangostana with
460
Multifunctional Activities for the Therapy of Alzheimer’s Disease. Neurochem. Res. 20
ACS Paragon Plus Environment
Page 20 of 35
Page 21 of 35
Journal of Agricultural and Food Chemistry
461 462 463
2016, 41, 1806-1817. (27) Cen, J.; Shi, M.; Yang, Y.; Fu, Y.; Zhou, H.; Wang, M.; Su, Z.; Wei, Q., Isogarcinol is a new immunosuppressant. PLoS One 2013, 8, e66503.
464
(28) Li, J.; Tu, Y.; Tong, L.; Zhang, W.; Zheng, J.; Wei, Q., Immunosuppressive
465
activity on the murine immune responses of glycyrol from Glycyrrhiza uralensis via
466
inhibition of calcineurin activity. Pharm. Biol. 2010, 48, 1177-1184.
467
(29) Fu, Y.; Zhou, H.; Wang, M.; Cen, J.; Wei, Q., Immune regulation and
468
anti-inflammatory effects of isogarcinol extracted from Garcinia mangostana L.
469
against collagen-induced arthritis. J. Agric. Food Chem. 2014, 62, 4127-4134.
470
(30) Li, W.; Li, H.; Zhang, M.; Zhong, Y.; Wang, M.; Cen, J.; Wu, H.; Yang, Y.; Wei,
471
Q., Isogarcinol extracted from Garcinia mangostana L. ameliorates systemic lupus
472
erythematosus-like disease in a murine model. J. Agric. Food Chem. 2015, 63,
473
8452-8459.
474
(31) Cen, J.; Wang, M.; Jiang, G.; Yin, Y.; Su, Z.; Tong, L.; Ma, Y.; Gao, Y.; Wei, Q.,
475
The new immunosuppressant, isogarcinol, binds directly to its target enzyme
476
calcineurin, unlike cyclosporin A and tacrolimus. Biochimie 2015, 111, 119-124.
477
(32) Kuerten, S.; Javeri, S.; Tary-Lehmann, M.; Lehmann, P. V.; Angelov, D. N.,
478
Fundamental differences in the dynamics of CNS lesion development and
479
composition in MP4-and MOG peptide 35–55-induced experimental autoimmune
480
encephalomyelitis. Clin. Immunol. 2008, 129, 256-267.
481
(33) Wei, W.; Du, C.; Lv, J.; Zhao, G.; Li, Z.; Wu, Z.; Haskó, G.; Xie, X., Blocking
482
A2B adenosine receptor alleviates pathogenesis of experimental autoimmune 21
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
483
encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. The
484
Journal of Immunology 2013, 190, 138-146.
485
(34) Li, H.; Nourbakhsh, B.; Ciric, B.; Zhang, G.-X.; Rostami, A., Neutralization of
486
IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the
487
effector T cell population. The Journal of Immunology 2010, 185, 4095-4100.
488
(35) Jiang, Y.; Zou, Y.; Chen, S.; Zhu, C.; Wu, A.; Liu, Y.; Ma, L.; Zhu, D.; Ma, X.;
489
Liu, M., The anti-inflammatory effect of donepezil on experimental autoimmune
490
encephalomyelitis in C57 BL/6 mice. Multiple Sclerosis 2013, 73, 690-690.
491 492
(36) Berer, K.; Krishnamoorthy, G., Microbial view of central nervous system autoimmunity. FEBS Lett. 2014, 588, 4207–4213.
493
(37) Croxford, A. L.; Kurschus, F. C.; Waisman, A., Mouse models for multiple
494
sclerosis: historical facts and future implications. Biochimica et Biophysica Acta
495
(BBA)-Molecular Basis of Disease 2011, 1812, 177-183.
496
(38) Ciftci, O.; Ozcan, C.; Kamisli, O.; Cetin, A.; Basak, N.; Aytac, B., Hesperidin, a
497
citrus flavonoid, has the ameliorative effects against experimental autoimmune
498
encephalomyelitis (EAE) in a C57BL/J6 mouse model. Neurochem. Res. 2015, 40,
499
1111-1120.
500
(39) Höftberger, R.; Leisser, M.; Bauer, J.; Lassmann, H., Autoimmune encephalitis
501
in humans: how closely does it reflect multiple sclerosis? Acta neuropathologica
502
communications 2015, 3, 1.
503
(40) Klawiter, E. C.; Schmidt, R. E.; Trinkaus, K.; Liang, H.-F.; Budde, M. D.;
504
Naismith, R. T.; Song, S.-K.; Cross, A. H.; Benzinger, T. L., Radial diffusivity 22
ACS Paragon Plus Environment
Page 22 of 35
Page 23 of 35
Journal of Agricultural and Food Chemistry
505
predicts demyelination in ex vivo multiple sclerosis spinal cords. NeuroImage 2011,
506
55, 1454-1460.
507 508 509 510 511
(41) Taheri, S.; Rosenberg, G. A.; Ford, C., Quantification of blood-to-brain transfer rate in multiple sclerosis. Multiple sclerosis and related disorders 2013, 2, 124-132. (42) Zhou, L.; Chong, M. M.; Littman, D. R., Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30, 646-655. (43) Yang, X. O.; Pappu, B. P.; Nurieva, R.; Akimzhanov, A.; Kang, H. S.; Chung, Y.;
512
Ma, L.; Shah, B.; Panopoulos, A. D.; Schluns, K. S., T helper 17 lineage
513
differentiation is programmed by orphan nuclear receptors RORα and RORγ.
514
Immunity 2008, 28, 29-39.
515 516
(44) Lassmann, H.; van Horssen, J., The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011, 585, 3715-3723.
517
(45) Ivanov, I. I.; McKenzie, B. S.; Zhou, L.; Tadokoro, C. E.; Lepelley, A.; Lafaille,
518
J. J.; Cua, D. J.; Littman, D. R., The orphan nuclear receptor RORγt directs the
519
differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126,
520
1121-1133.
521
(46) Hubert, M. T.; Thayer, T. C.; Steele, C.; Cuda, C. M.; Morel, L.; Piganelli, J. D.;
522
Mathews, C. E., NADPH oxidase deficiency regulates Th lineage commitment and
523
modulates autoimmunity. The Journal of Immunology 2010, 185, 5247-5258.
524
(47) Ghoreschi, K.; Brück, J.; Kellerer, C.; Deng, C.; Peng, H.; Rothfuss, O.;
525
Hussain, R. Z.; Gocke, A. R.; Respa, A.; Glocova, I., Fumarates improve psoriasis and
526
multiple sclerosis by inducing type II dendritic cells. The Journal of experimental 23
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
527
Page 24 of 35
medicine 2011, 208, 2291-2303.
528
(48) Pieme, C. A.; Ambassa, P.; Yankep, E.; Saxena, A. K., Epigarcinol and
529
isogarcinol isolated from the root of Garcinia ovalifolia induce apoptosis of human
530
promyelocytic leukemia (HL-60 cells). BMC Res. Notes 2015, 8, 1.
531
(49) Kroenke, M. A.; Carlson, T. J.; Andjelkovic, A. V.; Segal, B. M., IL-12–and
532
IL-23–modulated T cells induce distinct types of EAE based on histology, CNS
533
chemokine profile, and response to cytokine inhibition. The Journal of experimental
534
medicine 2008, 205, 1535-1541.
535
(50)
Mika,
A.;
Stepnowski,
P.,
Current
methods
of
the
analysis
of
536
immunosuppressive agents in clinical materials: A review. J. Pharm. Biomed. Anal.
537
2016.
538
24
ACS Paragon Plus Environment
Page 25 of 35
Journal of Agricultural and Food Chemistry
539
FIGURE CAPTIONS
540 541
Figure 1. Isogarcinol. (A) Chemical structure. (B) Splenocytes from EAE mice
542
stimulated with MOG35-55 (20 µg/mL), and from normal congenic mice stimulated
543
with ConA (5 µg/mL), were cultured in the presence of different concentrations of
544
isogarcinol, and their proliferation was measured by the CCK-8 assay after 48 h (n =
545
3). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01.
546 547
Figure 2. Isogarcinol ameliorates the clinical signs of EAE induced as described in
548
MATERIALS and METHODS. (A) Mean clinical scores of EAE mice given vehicle,
549
isogarcinol (100 mg/kg) or CsA (50 mg/kg) by oral gavage daily, starting from 11 d
550
postimmunization. (B) Mean body weights of normal, vehicle-, isogarcinol- and
551
CsA-treated EAE mice on day 18 postimmunization (n = 8). (C) H&E and Luxol Fast
552
Blue (LFB) staining of spinal cords from normal mice and EAE mice treated with
553
vehicle, isogarcinol or CsA on day 18 postimmunization. (D) Quantification of CNS
554
infiltrates (n = 4). (E) Pathology scores for demyelination (n = 4). (F) The absolute
555
number of MNCs in the CNS was counted in normal, vehicle- and isogarcinol-treated
556
EAE mice on day 18 postimmunization (n = 4). All values are expressed as mean ±
557
SEM. ***P < 0.001; ###P < 0.001.
558 559
Figure 3. Isogarcinol reduces intracranial lesions and meningeal enhancement in EAE.
560
In vivo 3.0 T MRI scanned brains of normal mice or EAE mice treated with vehicle,
561
isogarcinol or CsA on day 18 postimmunization. (A-D) T1-weighted image. (E-G)
562
T1-weighted image obtained 10 min after injection of Gd-DTPA enhancer. Arrows
563
indicate focal lesions in the subcortex and enhancements in the meninges (F). 25
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
564 565
Figure 4. Effect of isogarcinol and CsA treatments on hematopoietic function in EAE
566
mice. White blood cell counts (A), red blood cell counts (B), hemoglobin
567
concentrations (C) and platelet counts (D) were obtained with an automated
568
hematologic analyzer after the last day of treatment (n = 8). Results are expressed as
569
means ± SEM. *P